CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 8,087 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 8,087 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $18.25, for a total value of $147,587.75. Following the completion of the sale, the chief technology officer directly owned 166,912 shares of the company’s stock, valued at $3,046,144. The trade was a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total transaction of $13,951.95.
• On Friday, January 2nd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $21.18, for a total transaction of $235,352.16.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded up $0.19 during midday trading on Thursday, reaching $17.96. 63,397 shares of the company were exchanged, compared to its average volume of 343,432. The stock has a market cap of $676.03 million, a P/E ratio of -12.22 and a beta of 1.12. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $24.33. The stock has a fifty day simple moving average of $20.91 and a 200 day simple moving average of $16.41. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. On average, research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CBLL has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. JPMorgan Chase & Co. lowered their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. TD Cowen reissued a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, BTIG Research restated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CBLL. TimesSquare Capital Management LLC boosted its stake in shares of CeriBell by 48.5% during the 2nd quarter. TimesSquare Capital Management LLC now owns 796,945 shares of the company’s stock worth $14,927,000 after acquiring an additional 260,116 shares in the last quarter. Geode Capital Management LLC raised its holdings in CeriBell by 55.4% during the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after purchasing an additional 159,698 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its position in CeriBell by 161.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after purchasing an additional 3,502 shares in the last quarter. Intech Investment Management LLC acquired a new stake in CeriBell in the second quarter valued at $266,000. Finally, JPMorgan Chase & Co. increased its position in shares of CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after buying an additional 374,179 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.